Investment House LLC Cuts Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Investment House LLC lowered its position in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 3.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 161,574 shares of the medical research company's stock after selling 6,280 shares during the period. Investment House LLC's holdings in Edwards Lifesciences were worth $11,961,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FSA Wealth Management LLC bought a new stake in Edwards Lifesciences in the third quarter worth $30,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Edwards Lifesciences in the 4th quarter worth about $30,000. Prospera Private Wealth LLC purchased a new stake in Edwards Lifesciences during the 3rd quarter valued at about $32,000. Avior Wealth Management LLC increased its stake in Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock valued at $35,000 after purchasing an additional 308 shares in the last quarter. Finally, Roble Belko & Company Inc purchased a new position in Edwards Lifesciences in the fourth quarter worth about $46,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company's stock, valued at approximately $3,189,770.56. This trade represents a 16.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Bernard J. Zovighian sold 6,164 shares of Edwards Lifesciences stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the sale, the chief executive officer now owns 59,083 shares in the company, valued at approximately $4,106,859.33. This represents a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 51,303 shares of company stock worth $3,715,776. Corporate insiders own 1.29% of the company's stock.

Remove Ads

Edwards Lifesciences Stock Performance

Shares of NYSE:EW traded down $0.50 during mid-day trading on Friday, reaching $70.46. 7,144,270 shares of the company traded hands, compared to its average volume of 4,616,653. The company's 50 day moving average price is $71.42 and its 200-day moving average price is $70.37. The firm has a market cap of $41.42 billion, a PE ratio of 10.11, a PEG ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, equities analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Morgan Stanley raised their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. Barclays lifted their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Canaccord Genuity Group upped their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a report on Thursday, February 13th. Royal Bank of Canada reiterated an "outperform" rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Finally, The Goldman Sachs Group upped their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a "buy" rating in a research note on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have given a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.